- Home
- GLU vs ALLK Comparison
GLU vs ALLK Comparison
Compare GLU & ALLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLU
- ALLK
- Stock Information
- Founded
- GLU 2004
- ALLK 2012
- Country
- GLU United States
- ALLK United States
- Employees
- GLU N/A
- ALLK N/A
- Industry
- GLU Finance/Investors Services
- ALLK Biotechnology: Pharmaceutical Preparations
- Sector
- GLU Finance
- ALLK Health Care
- Exchange
- GLU Nasdaq
- ALLK Nasdaq
- Market Cap
- GLU 95.9M
- ALLK 101.0M
- IPO Year
- GLU N/A
- ALLK 2018
- Fundamental
- Price
- GLU $16.48
- ALLK $0.91
- Analyst Decision
- GLU
- ALLK Hold
- Analyst Count
- GLU 0
- ALLK 5
- Target Price
- GLU N/A
- ALLK $1.67
- AVG Volume (30 Days)
- GLU 12.4K
- ALLK 703.0K
- Earning Date
- GLU 01-01-0001
- ALLK 11-06-2024
- Dividend Yield
- GLU 8.60%
- ALLK N/A
- EPS Growth
- GLU N/A
- ALLK N/A
- EPS
- GLU 0.62
- ALLK N/A
- Revenue
- GLU N/A
- ALLK N/A
- Revenue This Year
- GLU N/A
- ALLK N/A
- Revenue Next Year
- GLU N/A
- ALLK N/A
- P/E Ratio
- GLU $22.50
- ALLK N/A
- Revenue Growth
- GLU N/A
- ALLK N/A
- 52 Week Low
- GLU $11.61
- ALLK $0.54
- 52 Week High
- GLU $15.40
- ALLK $3.41
- Technical
- Relative Strength Index (RSI)
- GLU 56.85
- ALLK 39.60
- Support Level
- GLU $15.90
- ALLK $1.29
- Resistance Level
- GLU $16.48
- ALLK $1.56
- Average True Range (ATR)
- GLU 0.44
- ALLK 0.13
- MACD
- GLU 0.01
- ALLK -0.07
- Stochastic Oscillator
- GLU 37.66
- ALLK 2.52
About GLU Gabelli Global Utility of Beneficial Ownership
Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.